Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13870524 | 0.85 | ALDH1A1 (0.67) | ALDH1A1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL10843104 | 0.85 | ALDH1A1 (0.62) | ALDH1A1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL12796661 | 0.83 | ALDH1A1 (0.63) | ALDH1A1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL10373496 | 0.83 | ALDH1A1 (0.63) | ALDH1A1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL11259284 | 0.83 | ALDH1A1 (0.59) | ALDH1A1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL10684593 | 0.83 | ALDH1A1 (0.59) | ALDH1A1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL10996455 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MAPTRAB9A | |
| SCHEMBL10993559 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL13538726 | 0.82 | ALDH1A1 (0.59) | ALDH1A1MAPTRAB9ASMN1; SMN2NPC1 | |
| Isoxepac SCHEMBL24970 | 0.82 | AKR1B1 (0.81) | ALDH1A1MAPTRAB9ALMNAAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137619-A1 | CRYSTALLINE POLYMORPHIC FORMS OF OLOPATADINE HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | MEDICHEM, S.A. (ES) | 2010-06-03 | — | — | US | disclosed |
| EP-0497201-B1 | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO KK (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5478835-A | Acyl coenzyme A: acyltransferase inhibitors; treatment of hyperlipemia and arteriosclerosis | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| US-5340807-A | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0497201-A1 | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| EP-0038564-B1 | DIBENZ (B,E) OXEPIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | KYOWA HAKKO KOGYO CO., LTD (JP) | 1984-09-12 | — | — | EP | disclosed |
| US-4396550-A | ANTICHOLINERGIC, ANTIHISTIMINIC AGENTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1983-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137619-A1 | CRYSTALLINE POLYMORPHIC FORMS OF OLOPATADINE HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | ADRA1B, ADRA2A, ADRA2B | ALDH1A1 1936/4885MAPT 632/4885RAB9A 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.